8 completed, 1 recruiting, 1 terminated, 1 unknown. 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 8, Recruiting 1, Terminated 1, Unknown 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Banner Life Sciences LLC | 46 | 2021-05-14 | 2022-01-06 |
| Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis ANK-700, Placebo - Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Anokion SA | 34 | 2020-11-06 | 2025-05-31 |
| SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis Ixazomib (NINLARO®) capsules / Matching placebo capsules - Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 | Recruiting | Queen Mary University of London | 72 | 2020-06-15 | 2026-09-08 |
| Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control - Relapsing Remitting Multiple Sclerosis | Phase 1 | Terminated | Jeffrey Gelfand | 5 | 2018-11-16 | 2026-02-03 |
| Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects monomethyl fumarate 190 mg, dimethyl fumarate 240 mg - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Banner Life Sciences LLC | 50 | 2017-01-06 | 2022-12-30 |
| Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. olesoxime (TRO19622), placebo - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Hoffmann-La Roche | 44 | 2013-04-01 | 2016-11-22 |
| ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis ATX-MS-1467 - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Apitope Technology (Bristol) Ltd. | 43 | 2010-03-01 | 2015-02-16 |
| A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS BG00012 - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Biogen | 48 | 2009-02-28 | 2018-02-15 |
| Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis Helminth ova - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | University of Wisconsin, Madison | 17 | 2008-07-01 | 2019-02-06 |
| Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients Ritalin - Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive | Phase 1 | Unknown | Sheba Medical Center | 80 | 2003-06-01 | 2007-01-05 |
| Vitamin D Pilot Study in Patients With Multiple Sclerosis 19 nor vitamin d - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | University of Wisconsin, Madison | 1998-02-01 | 2015-10-05 |
Multiple Sclerosis, Relapsing-Remitting (11) · Multiple Sclerosis (5) · Multiple Sclerosis, Chronic Progressive (2)
Autoimmune Diseases (11) · Autoimmune Diseases of the Nervous System (11) · Demyelinating Autoimmune Diseases, CNS (11) · Demyelinating Diseases (11) · Immune System Diseases (11) · Nervous System Diseases (11) · Multiple Sclerosis (6) · Chronic Disease (2) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Dimethyl Fumarate (2) · monomethyl fumarate (2) · ATX-MS-1467 (1) · Capsules (1) · Fecal Microbiota Transplantation (1) · Methylphenidate (1) · Therapy with Helminths (1) · diroximel fumarate (1) · ixazomib (1) · olesoxime (1)
Banner Life Sciences LLC (2) · University of Wisconsin, Madison (2) · Anokion SA (1) · Apitope Technology (Bristol) Ltd. (1) · Biogen (1) · Hoffmann-La Roche (1) · Jeffrey Gelfand (1) · Queen Mary University of London (1) · Sheba Medical Center (1)
United States (5) · United Kingdom (2) · France (1) · Germany (1) · Israel (1) · Russia (1)
Franck Rousseau, MD (2) · Anat Achiron, MD PhD (1) · Jeffrey Gelfand, MD, MAS (1) · Jeremy Chataway (1) · John O Fleming, MD (1) · Nava Appleboim-Gavish, MA (1) · Yirmiyahu Harel, MD (1)
PMID 21372112, PMID 29064315, PMID 33797063, PMID 41758576
2018 (1)